Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Roth Capital analyst Jonathan Aschoff maintained a Buy rating on Moleculin Biotech (MBRX) on December 17 and set a price target of $5.00. The company’s shares closed last Thursday at $1.07.
There used to be lots of people until it became full of scandals
Can’t believe there is nobody on this message board for this ticker. Crazy
News coming soon...? I love this stock!
Here we go this is the start of the joy ride to heaven
Remember it’s a 3 day weekend upon us....and it’s sell off Friday
So buy some cheapies
News could break after hours or on Monday
I hate when this trades under a dollar and bid and asks move on the 1000’s of a penny.
Get back to a dollar already! Geez
I look forward to news from Moleculin and WPD Pharmaceuticals: Their drug WP1122 could kill Covid19? That would be great!
The smaller of the 5 will be the biggest rocket launch ??
Strong new out today. Top 5 emerging companies in Cancer Research.
https://www.prnewswire.com/news-releases/advanced-testing-options-help-alter-the-fight-against-cancer-301189192.html
* * $MBRX Video Chart 12-01-2020 * *
Link to Video - click here to watch the technical chart video
Like clockwork, watch the company announce a dilutive equity financing after the market closed today. They do this every time they issue a good press release
Some sad shit! Was thinking today was the day
Like I said, huge dumping... LOL. Nice shirt from 1.40...
no,MM took stops out now they run $2++++ mhop
They are dumping huge here...
News Out,,FDA approvals 3 $$$$$$
Just In: $MBRX Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020 PR Newswire HOUSTON, Nov. 13, 2020 HOUSTON , Nov. 13, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pha...
Find out more MBRX - Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020
The real problem here is that everything they claim might be true, but nothing will hit the actual markets to generate revenue for at least 4 to 5 years and that will be the ones in Trials currently.
So, no reasons to buy this and get left holding a bag here. The race between a reverse split and an FDA approved product from Moleculin will easily be won by the reverse split.
Jmho
Bill
"The question now is; Which will come first?"
I'm going with the chicken.!!
The question now is; Which will come first? A pop or a RS? Its' in the $.70 cent range now so it's tempting to buy.
Reverse Split and raising A/S
might as well be a penny stock
Amended Current Report Filing (8-k/a)
Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 11, 2020
MOLECULIN-LOGO_HORIZA55.JPG
MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
DELAWARE
001-37758
47-4671997
(State or Other Jurisdiction of Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification No.)
5300 Memorial Drive, Suite 950, Houston,TX 77007
(Address of principal executive offices and zip code)
(713) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X] Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock, par value $.001 per share
MBRX
The NASDAQ Stock Market LLC
EXPLANATORY NOTE
This Current Report on Form 8-K/A is being filed as an amendment to the Current Report on Form 8-K filed by Moleculin Biotech, Inc. (the "Company") on June 17, 2020 (the "Original 8-K"). The Original 8-K was filed, among other things, to report the results of the matters submitted to a vote by the Company’s stockholders at the Company’s 2020 annual meeting of stockholders held on June 15, 2020 pursuant to Item 5.07. The reported results were derived from a report received from the Company’s independent proxy tabulation firm and confirmed by an independent inspector of elections. Following the filing, the Company realized that the proxy tabulation firm’s report treated Proposal #4, regarding the approval of an increase the number of common stock authorized for issuance under the Company’s 2015 stock plan, as a routine proposal on which brokers would be permitted to use their discretionary authority to vote shares held as record owner. As such, the Company’s proxy tabulation firm did not report any broker non-votes on Proposal #4. After further review, the proxy tabulation firm confirmed that the foregoing treatment of Proposal #4 was an error and the proposal should have been treated as a non-routine matter. Subsequent to this determination, the Company received a corrected report from the Company’s proxy tabulation firm. The corrected number of votes cast for and against as well as the number of abstentions and broker non-votes as to all proposals are set forth below. The Company notes that the re-tabulation of the results after the meeting resulted in an immaterial change in the share calculations previously disclosed under the columns "Votes Withheld" and "Broker Non-Votes" for Proposal #1 (there was no change to the number of "Votes For"). The re-tabulation did not change the passage of any proposals, and all proposals were approved.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 15, 2020, the Company held its 2020 Annual Meeting of Stockholders (the "Annual Meeting"). As of March 23, 2020, the record date for the Annual Meeting, there were 53,227,700 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 41,131,579 shares, or 77.27%, were present in person or represented by proxy, which constituted a quorum. The holders of shares of our common stock are entitled to one vote for each share held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting.
Proposal 1. Election of Directors - The Company's stockholders elected Walter V. Klemp, Robert George, Michael Cannon and John Climaco to serve until the 2021 Annual Meeting of Stockholders of the Company, or until such person's successor is qualified and elected.
Director Name
Votes For
Votes Withheld
Broker Non-Votes
Walter V. Klemp
16,390,215
2,036,729
22,704,635
Robert George
15,472,188
2,954,756
22,704,635
Michael Cannon
15,941,344
2,485,600
22,704,635
John Climaco
15,973,315
2,453,629
22,704,635
Proposal 2. Ratify Grant Thornton LLP as Independent Registered Public Accountant - The Company's stockholders ratified the appointment of Grant Thornton, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2020, by the following vote:
2
Votes For
Votes Against
Abstain
39,454,292
1,180,065
497,222
Proposal 3. To Effect a Reverse Stock Split of the Outstanding Shares - - The Company’s stockholders authorized the Board of Directors, in its sole discretion, prior to the one-year anniversary of the Annual Meeting, to file an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at one of the following reverse stock split ratios, 1-for-2, 1-for-3, 1-for-4, 1-for-5, 1-for-6, 1-for-7, or 1-for-8. As of the date hereof, the Company's Board of Directors has not made any determination on the filing of such amendment. The voting on this proposal is set forth below:
Votes For
Votes Against
Abstain
26,983,694
13,582,402
565,483
Proposal 4. To Increase the Number of Common Stock Authorized for Issuance under the 2015 Plan - The Company’s stockholders approved an increase in the number of shares of common stock authorized for issuance under the 2015 Plan by 6,000,000 shares.
The voting on this proposal is set forth below:
Votes For
Votes Against
Abstain
Broker Non-Votes
14,496,928
3,791,840
138,176
22,704,635
Proposal 5. To authorize an Adjournment of the Annual Meeting - To authorize an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve of the foregoing proposals.
Votes For
Votes Against
Abstain
31,734,118
8,579,342
818,119
Adjournment of the Annual Meeting was necessary due to public health concerns.
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOLECULIN BIOTECH, INC.
Date: August 4, 2020
By: /s/ Jonathan P. Foster
Jonathan P. Foster
Chief Financial Officer
3
bahahaha you have no clue MBRX I bought a lot of shares here $4 Target price easy peasy lemon squeezy woohoooooo
MBRX the next big winner here woohoooooooo $4 TARGET price WOOHOOOOOOOOOOOOOOO
Yes, and the stock closed down. I gave up on the stock.
Article posted on Sterling Pharma Solutions website: https://www.sterlingpharmasolutions.com/sterling-signs-deal-to-produce-potential-covid-19-drug-candidate-for-moleculin/#content-start
Listen to the PHD-discussion from MBRX, announcing Moleculin's-discovery of WP1122 effectiveness for Covid-19, from April 16, 2020 resulting in
100% suppression of the Sars-Cov-2.....Potentially, this molecule would be part of a cure for the coronavirus, not a vaccine for it.
https://edge.media-server.com/mmc/p/xihchttv
In my opinion, the academic discussion on this level, will go over the heads of 99.5 % of the folks here: but fortunately, here is a simpler analysis for us:
https://finance.yahoo.com/news/moleculin-biotech-mbrx-stock-outpacing-153003277.html
This post is only my own opinion, and I would invite you folks to please do your own Due Diligence.
I agree. This company can’t possibly compete in this space. There will likely be multiple vaccines before this company is done testing in Petri dishes.
Yeah. Easy money for the directors. For shareholders not so much.
They just gave Phizer 2 billion dollars big Pharma is hoping to kill all research except their own.There is far too much lobbying and corruption in this industry health care results are not always the motivator for the evil drug empire.I am holding a good load of MBRX they and other promising companies need a kick start with a few million I doubt Phizer and the big boys need government handouts.
Haha. I was thinking the same thing when I saw that.
And Clay showed up time to sell if you haven’t already ! When Clay post his bs the stock always drops ! Get ready for a clay attack!
* * $MBRX Video Chart 07-21-2020 * *
Link to Video - click here to watch the technical chart video
if they didn't have proof.that would be fraudulent.
i not kidding about data. they should have it.
Followers
|
90
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3504
|
Created
|
06/17/16
|
Type
|
Free
|
Moderators |
WALTER V. KLEMP
President, CEO and Chairman
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |